These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 7069705)

  • 1. Catechol O-methyltransferase. 12. Affinity labeling the active site with the oxidation products of 5,6-dihydroxyindole.
    Borchardt RT; Bhatia P
    J Med Chem; 1982 Mar; 25(3):263-71. PubMed ID: 7069705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catechol O-methyltransferase. 7. Affinity labeling with the oxidation products of 6-aminodopamine.
    Borchardt RT; Smissman EE; Nerland D; Reid JR
    J Med Chem; 1976 Jan; 19(1):30-7. PubMed ID: 1246049
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Catechol O-methyltransferase. 9. Mechanism of inactivation by 6-hydroxydopamine.
    Borchardt RT; Reid JR; Thakker DR
    J Med Chem; 1976 Oct; 19(10):1201-9. PubMed ID: 994150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Catechol O-methyltransferase. 6. Affinity labeling with N-haloacetyl-3,5-dimethoxy-4-hydroxyphenylalkylamines.
    Borchardt RT; Thakker DR
    J Med Chem; 1975 Feb; 18(2):152-8. PubMed ID: 1120981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Catechol O-methyltransferase. 11. Inactivation by 5-hydroxy-3-mercapto-4-methoxybenzoic acid.
    Borchardt RT; Huber JA
    J Med Chem; 1982 Mar; 25(3):321-3. PubMed ID: 7069707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Affinity labeling of catechol O-methyltransferase by N-haloacetyl derivatives of 3,5-dimethoxy-4-hydroxyphenylethylamine and 3,4-dimethoxy-5-hydroxyphenylethylamine. Kinetics of inactivation.
    Borchardt RT; Thakker DR
    Biochemistry; 1975 Oct; 14(20):4543-51. PubMed ID: 240407
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure-based design, synthesis, and in vitro evaluation of bisubstrate inhibitors for catechol O-methyltransferase (COMT).
    Masjost B; Ballmer P; Borroni E; Zürcher G; Winkler FK; Jakob-Roetne R; Diederich F
    Chemistry; 2000 Mar; 6(6):971-82. PubMed ID: 10785817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of catechol-O-methyltransferase by 1-vinyl derivatives of nitrocatechols and nitroguaiacols. Kinetics of the irreversible inhibition by 3-(3-hydroxy-4-methoxy-5-nitro benzylidene)-2,4-pentanedione.
    Pérez RA; Fernández-Alvarez E; Nieto O; Piedrafita FJ
    Biochem Pharmacol; 1993 May; 45(10):1973-81. PubMed ID: 8512582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-electron oxidation of C(2) and C(3) methyl substituted 5,6-dihydroxyindoles: model pathways of melanogenesis.
    al-Kazwini AT; O'Neill P; Adams GE; Cundall RB; Maignan J; Junino A
    Melanoma Res; 1994 Dec; 4(6):343-50. PubMed ID: 7703713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inhibition of catechol-O-methyltransferase by 6,7-dihydroxy-3,4-dihydroisoquinolines related to dopamine: demonstration using liquid chromatography and a novel substrate for O-methylation.
    Cheng BY; Origitano TC; Collins MA
    J Neurochem; 1987 Mar; 48(3):779-86. PubMed ID: 2433397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kinetic and inhibition studies on catechol-O-methyltransferase affinity labelling by N-(3,4-dihydroxyphenyl)maleimide.
    Piedrafita FJ; Fernandez-Alvarez E; Nieto O; Tipton KF
    Biochem J; 1992 Sep; 286 ( Pt 3)(Pt 3):951-8. PubMed ID: 1417755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of human liver catechol-O-methyltransferase by tea catechins and their metabolites: structure-activity relationship and molecular-modeling studies.
    Chen D; Wang CY; Lambert JD; Ai N; Welsh WJ; Yang CS
    Biochem Pharmacol; 2005 May; 69(10):1523-31. PubMed ID: 15857617
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catechol O-methyltransferase. 10. 5-Substituted 3-hydroxy-4-methoxybenzoic acids (isovanillic acids) and 5-substituted 3-hydroxy-4-methoxybenzaldehydes (isovanillins) as potential inhibitors.
    Borchardt RT; Huber JA; Houston M
    J Med Chem; 1982 Mar; 25(3):258-63. PubMed ID: 7069704
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Labeling of catechol-O-methyltransferase with N-haloacetyl derivatives.
    Borchardt RT; Thakker DR
    Methods Enzymol; 1977; 46():554-61. PubMed ID: 909444
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of human catechol-O-methyltransferase-mediated dopamine O-methylation by daphnetin and its Phase II metabolites.
    Liang SC; Ge GB; Xia YL; Pei-Pei D; Ping W; Qi XY; Cai-Xia T; Ling Y
    Xenobiotica; 2017 Jun; 47(6):498-504. PubMed ID: 27435571
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular mechanisms controlling the rate and specificity of catechol O-methylation by human soluble catechol O-methyltransferase.
    Lautala P; Ulmanen I; Taskinen J
    Mol Pharmacol; 2001 Feb; 59(2):393-402. PubMed ID: 11160877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetic inhibitory profile of BIA 3-202, a novel fast tight-binding, reversible and competitive catechol-O-methyltransferase inhibitor.
    Bonifácio MJ; Vieira-Coelho MA; Soares-da-Silva P
    Eur J Pharmacol; 2003 Jan; 460(2-3):163-70. PubMed ID: 12559377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methyl conjugation in uraemia: catechol-O-methyltransferase.
    Pazmiño PA; Weinshilboum RM
    Br J Clin Pharmacol; 1980 Nov; 10(5):509-18. PubMed ID: 7437264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitory Effect of Bovine Lactoferrin on Catechol-O-Methyltransferase.
    Ikeda M; Iijima H; Shinoda I; Iwamoto H; Takeda Y
    Molecules; 2017 Aug; 22(8):. PubMed ID: 28825621
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ontogenic aspects of liver and kidney catechol-O-methyltransferase sensitivity to tolcapone.
    Vieira-Coelho MA; Soares-da-Silva P
    Br J Pharmacol; 1996 Feb; 117(3):516-520. PubMed ID: 8821542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.